Aptose Biosciences Goes Private in Hanmi Deal, Ending Public Trading and Paving Way for Oncology Integration
Canadian oncology firm Aptose exits public markets after Hanmi acquisition, offering premium liquidity but ending future independent upside for investors.
3 minutes to read
